Heron Therapeutics Inc   (HRTX)
Other Ticker:  
Price: $3.2400 $-0.07 -2.115%
Day's High: $3.38 Week Perf: 9.09 %
Day's Low: $ 3.17 30 Day Perf: -10.99 %
Volume (M): 1,562 52 Wk High: $ 3.93
Volume (M$): $ 5,062 52 Wk Avg: $2.08
Open: $3.31 52 Wk Low: $0.50

 Market Capitalization (Millions $) 470
 Shares Outstanding (Millions) 145
 Employees 336
 Revenues (TTM) (Millions $) 123
 Net Income (TTM) (Millions $) -120
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 2

Heron Therapeutics Inc
Heron Therapeutics Inc. is a pharmaceutical company that is focused on the development and commercialization of innovative therapies to address unmet medical needs. The company is dedicated to providing patients with safe and effective alternatives to existing treatments that do not adequately address their conditions or that may be associated with undesirable side effects.

Heron Therapeutics was founded in 1983 and is based in San Diego, California. The company operates under the leadership of CEO Barry Quart, who has been with the company since 2000. The company has a team of over 300 employees who work tirelessly to develop new and innovative treatments that improve patient outcomes.

Heron Therapeutics has developed a proprietary drug delivery system called Sustained Release (SR) technology, which is used to develop long-acting formulations of existing drugs. The technology allows for drugs to be released over an extended period, which can eliminate the need for multiple dosing throughout the day. SR technology has been used to develop numerous products in the Heron pipeline, including Zynrelef (bupivacaine and meloxicam), a recently FDA-approved drug for postoperative pain management.

Heron Therapeutics focuses on developing products for pain management, cancer supportive care, and rare diseases. The company's lead product candidate, HTX-011, is a novel local anesthetic that is being developed for postoperative pain management. The drug, which is administered during surgery, has been shown to provide superior pain relief compared to existing therapies and may reduce the need for opioids to manage postoperative pain.

In addition to its research and development efforts, Heron Therapeutics has a focus on commercialization. The company has a dedicated sales and marketing team that is responsible for launching new products and promoting existing products to healthcare professionals.

Overall, Heron Therapeutics is a biotechnology company that is dedicated to advancing medical treatments for unmet medical needs. With a focus on innovation, research and development, and commercialization, the company is well-positioned for continued growth and success in the industry.

   Company Address: 4242 Campus Point Court San Diego 92121 CA
   Company Phone Number: 251-4400   Stock Exchange / Ticker: NASDAQ HRTX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Stocks on the Move

Heron Therapeutics Inc. A Rising Biotech Star with Promising Future

Published Wed, Jul 3 2024 10:15 AM UTC

In this week, Heron Therapeutics Inc shares are trailing the performance of the entire market. However, recent developments and key insights suggest a strong growth potential for the company. With a series of positive announcements and a focus on innovative solutions in the biotechnology sector, Heron Therapeutics is positioning itself as a rising star in the industry.On Jul...

Heron Therapeutics Inc

Heron Therapeutics Inc: Unraveling the Mystery Behind Its Recent Stock Decline and Exploring Key Financial Metrics

In the ever-evolving world of finance, keeping track of a company's performance is crucial for investors and industry analysts. One such company that has experienced notable changes in recent trading sessions is Heron Therapeutics Inc. This article aims to shed light on the stock's recent decline, year-to-date performance, and provide an overview of the key financial metrics for the company.
Declining Stock Performance:
Over the course of the last five trading days, Heron Therapeutics Inc's stock experienced a significant downturn, falling by -20.89%. This decline adds to its year-to-date performance, which currently stands at -75.91%. Such a drop raises concerns among investors and underscores the need to analyze the factors that may have contributed to this downward trend.

Heron Therapeutics Inc

Heron Therapeutics Inc Faces Persistent Losses with a Shortfall of $-0.35 per Share Despite Revenue Growth in April-June 2023 Period

Heron Therapeutics Inc (HRTX) recently reported an increase in revenue by 14.955% in the April to June 30, 2023 period, compared to the corresponding reporting period from the previous year. However, despite this revenue growth, the Major Pharmaceutical Preparations company incurred a loss of $-0.35 per share. This indicates that although the company's top line is expanding, it is not able to generate profits.
When comparing the earnings from the previous reporting period, Heron Therapeutics Inc observed a 7.25% increase in revenue from $29.62 million. Unfortunately, the company's shortfall also grew from $-0.27 per share, adding to concerns about its financial performance.

Heron Therapeutics Inc

1. Heron Therapeutics Inc. Generates Impressive Revenue Surge, but Profitability Eludes in Recent Fiscal Period

Heron Therapeutics Inc., a major pharmaceutical preparations company, recently announced in their first quarter financial report for 2023 that they experienced a surge in revenue by 26.252% to $29.62 million compared to the same period from the previous year. While this may seem like positive news, it?s important to note that the company lost money at $-0.27 per share. This is a significant increase in deficit from the preceding period which was $-0.15 per share, and their revenue also decreased by -1.375% from $30.03 million.
Despite the significant loss in earnings per share, Heron Therapeutics remains focused on improving their expansion prospects by increasing expenditures, while also trying to offset the negative impacts of compensation worries. This is further complicated by a labor shortage currently being experienced in the industry. As a result, they are working on adjusting their pricing strategy to compensate for these challenges.


Heron Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com